Form 4: Silence Therapeutics Director Boosts Stake with ADS Purchases

Richard Ian Griffiths, a Director and 10% owner of Silence Therapeutics plc, acquired additional American Depositary Shares on July 29 and July 30, 2025, increasing his indirect beneficial ownership.

Summary

• Richard Ian Griffiths, a Director and 10% owner of Silence Therapeutics plc (SLN), reported two transactions involving the acquisition of American Depositary Shares (ADS).
• On July 29, 2025, Mr. Griffiths acquired 14,559 American Depositary Shares at a price of $6.2 per ADS.
• On July 30, 2025, he acquired an additional 8,923 American Depositary Shares at a price of $6.14 per ADS.
• Each American Depositary Share is immediately convertible into three ordinary shares for no consideration and has no expiration date.
• Following these transactions, Mr. Griffiths' indirect beneficial ownership, held through Cream Capital Limited, increased to 11,807,485 ordinary shares.

Sentiment

Score: 7

Explanation: The acquisition of additional shares by a director and significant owner indicates confidence in the company's prospects, which is generally a positive signal for investors.

Positives

• A Director and 10% owner, Richard Ian Griffiths, increased his stake in Silence Therapeutics plc through the purchase of American Depositary Shares.
• Insider buying can signal management's confidence in the company's future prospects.

Future Outlook

No forward-looking statements or guidance are provided.

Industry Context

This filing reflects an insider's increased investment in a biotechnology company, which could be interpreted as a positive signal within the sector, especially if the company is nearing significant clinical milestones or commercialization.

Related Party Transactions

• The securities are held by Cream Capital Limited ("Cream"), where Mr. Griffiths is a director and the controlling shareholder. This constitutes a related party transaction as Mr. Griffiths is indirectly acquiring shares through an entity he controls.

Stakeholder Impact

• Shareholders: The insider purchases may instill confidence among existing and potential shareholders, potentially leading to increased demand for the stock.

Key Dates

Recommendation

The insider purchases by a director and 10% owner, Richard Ian Griffiths, signal strong internal confidence in Silence Therapeutics plc's future. While this is a positive indicator, a Form 4 filing does not provide comprehensive financial or operational details to warrant a 'buy' recommendation without further due diligence. Therefore, a 'hold' recommendation is appropriate for existing investors, suggesting continued confidence, and for potential investors, it serves as a positive signal to conduct further research.

Keywords

Silence Therapeutics, SLN, Form 4, Insider Trading, Director Purchase, American Depositary Shares, ADS, Beneficial Ownership, Richard Ian Griffiths, Cream Capital Limited, Biotechnology, Pharmaceuticals